Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 17

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 17
---
2.1 | % |     |     |  0.9 | %                         |
| Core selling, general and administrative (SG&A) expenses |     |            |     |  -538.5 |     |           |     |  -509.7 |     |          |     |   28.9 |     |  -5.4 | % |     |     | -2.0 | %                         |
| Core research and development (R&D) expenses             |     |            |     |  -344.1 |     |           |     |  -305.5 |     |          |     |   38.7 |     | -11.2 | % |     |     | -7.5 | %                         |
| Core operating profit                                    |     |            |     |   719.9 |     |           |     |   639.2 |     |          |     |  -80.7 |     | -11.2 | % |     |     | -8.8 | %                         |

During the periods presented, these items fluctuated as follows:

#### Core Cost of Sales
Core Cost of Sales was JPY 765.2 billion (JPY -16.3 billion and -2.1% AER, +0.9% CER). The decrease was primarily due to the decrease in revenue and the appreciation of the Japanese yen, largely offset by higher costs resulting from a change in product mix, mainly reflecting the continued impact of generic erosion, particularly for VYVANSE in the U.S.

<div align='center'>7</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Six-month

Period Ended September 30, 2025 (Consolidated)

Core Selling, General and Administrative (SG&A) Expenses

Core SG&A expenses were JPY 509.7 billion (JPY -28.9 billion and -5.4% AER, -2.0% CER). The decrease was primarily due to the appreciation of the Japanese yen and cost savings under the enterprise-wide efficiency program, which led mainly to reductions in personnel expenses.

#### Core Research and Development (R&D) Expenses
Core R&D expenses were JPY 305.5 billion (JPY -38.7 billion and -11.2% AER, -7.5% CER). The decrease was mainly due to